- Announce that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University
- As part of MMP’s mission to diversify and offer new products to consumers, with the award of the NSERC Engage partnership grant, MMP will establish a first research collaboration with McGill University and plans to invest in this program both financially and with in-kind contributions
OTTAWA, ONTARIO–(Oct. 19, 2016) – Grow Pros MMP Inc. (MMP), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP) is pleased to announce that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to MMP and Dr. Stan Kubow of McGill University.
As part of MMP’s mission to diversify and offer new products to consumers, with the award of the NSERC Engage partnership grant, MMP will establish a first research collaboration with McGill University and plans to invest in this program both financially and with in-kind contributions to pursue its research and development objectives and become a world leader in the development and commercialization of Cannabis-based products.
“The partnership with McGill University is in line with MMP’s vision to expand commercial operations and prepare to launch Cannabis sativa-derived supplement/retail or drug products for the North American market. This project will allow the development of intellectual property to protect future products that would be commercialized by TBP,” commented Ryan Brown.
“The proposed collaboration between Dr S. Kubow, Associate Professor, McGill University, relates to MMP’s need to develop an extraction process and to develop products using specific fractions of the plant Cannabis sativa. Fractions with the highest dermal and oral absorption will subsequently be characterized to further understand the pharmacology of these extracts,” commented Dr. Randy Ringuette, Ph.D. Medical Researcher, MMP Inc.
Dr. Stan Kubow stated, “We are excited by the collaboration with MMP that will allow us to utilize systematic state-of-the-art research methodologies to identify bioactives from Cannabis sativa for the development of science-based consumer products.”
According to Mr. A. Rancourt CEO of TBP, “We are very pleased by the decision of NSERC to award this partnership grant. This has implications for both MMP and AgroTek.” He added, “This is in line with TBP’s vision to make MMP a leader in the development of Cannabis sativa derived products for the consumer market and for the commercialization of natural supplements derived from Cannabis sativa by AgroTek.”
About Dr. Stan Kubow
Dr. S. Kubow, Ph.D. is an Associate Professor at the School of Dietetics and Human Nutrition, McGill University. His research interests include the impact of nutritional interventions on a variety of disease outcomes and metabolic disorders using technologically modified food extracts and isolates with enhanced bioactivity including phytochemical extracts, whey and soy proteins and probiotics. These studies have been focused upon oxidative stress, inflammatory indices, lipoprotein, fatty acid and glucose metabolism as related to cell signaling pathways and disease pathogenesis.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 421-8402
[email protected]
